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Abstract
Glaucoma is the leading cause of irreversible vision loss. Ocular hypertension is a major risk factor for glaucoma and
recent work has demonstrated critical early neuroinflammatory insults occur in the optic nerve head following
ocular hypertension. Microglia and infiltrating monocytes are likely candidates to drive these neuroinflammatory
insults. However, the exact molecular identity / transcriptomic profile of microglia following ocular hypertensive
insults is unknown. To elucidate the molecular identity of microglia after long-term exposure to ocular
hypertension, we used a mouse model of glaucoma (DBA/2 J). We performed RNA-sequencing of microglia mRNA
from the optic nerve head at a time point following ocular hypertensive insults, but preceding detectable
neurodegeneration (with microglia identified as being CD45lo/CD11b+/CD11c−). Furthermore, RNA-sequencing was
performed on optic nerve head microglia from mice treated with radiation therapy, a potent therapy preventing
neuroinflammatory insults. Transcriptomic profiling of optic nerve head microglia mRNA identifies metabolic
priming with marked changes in mitochondrial gene expression, and changes to phagocytosis, inflammatory, and
sensome pathways. The data predict that many functions of microglia that help maintain tissue homeostasis are
affected. Comparative analysis of these data with data from previously published whole optic nerve head tissue or
monocyte-only samples from DBA/2 J mice demonstrate that many of the neuroinflammatory signatures in these
data sets arise from infiltrating monocytes and not reactive microglia. Finally, our data demonstrate that
prophylactic radiation therapy of DBA/2 J mice potently abolishes these microglia metabolic transcriptomic changes
at the same time points. Together, our data provide a unique resource for the community to help drive further
hypothesis generation and testing in glaucoma.
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Background
Glaucoma is one of the most common neurodegenera-
tions affecting an estimated 80 million people worldwide
[1]. It is a complex and multifactorial disease characterised
by the progressive dysfunction and loss of retinal ganglion
cells and their axons (that make up the optic nerve). A
common theme between animal models and human glau-
coma is the activation or reactivity of glial cells in the ret-
ina, optic nerve, and optic nerve head [2–7]. Activated
microglia are known to affect the progression of neurode-
generative diseases due to their influence over homeo-
static and immune responses. Ongoing microglial
responses may be protective, damage neural tissue, and/or
lead to chronic inflammation. Given the primary role of
microglia in regulating neuroinflammation (such as in
Alzheimer’s disease [8–11]), identifying any dysregulation
of microglia is of paramount importance for the develop-
ment of neuroprotective treatments [12].
Microglia perform a diverse series of functions to sup-
port neural activity, including maintenance of synapses
and axons, removal of cellular debris, surveillance for in-
jury and pathogens, and co-ordination of neuroinflam-
matory responses [12–17]. These functions require
microglia to continuously sense and respond to their en-
vironment. Many environmental cues lead to changes in
microglial gene expression that support functional
specialization. Genome-wide gene expression profiling
has been used to identify important functional differ-
ences between microglia in normal physiological, neu-
roinflammatory, and neurodegenerative conditions [18–
20]. However, microglia-specific transcriptomic profiles
in the normal and glaucomatous optic nerve head are
yet to be generated. These previous studies support the
need for transcriptomic profiling of microglia in glau-
coma relevant tissues.
The DBA/2 J mouse develops neurodegeneration due
to elevated intraocular pressure (IOP) with hallmark fea-
tures of an inherited, chronic human glaucoma. An im-
portant, human relevant aspect of disease in DBA/2 J
mice is elevated IOP-related injury at the optic nerve
head (ONH). Elevated IOP is a major risk factor for hu-
man glaucoma. In our colony, elevated IOP develops
from 6months of age, and by 9 months of age there are
signs of injury at the ONH [21, 22]. The neurodegenera-
tion it triggers is complete in the majority of eyes by 12
months of age (based on retinal ganglion cell soma and
axon loss) [22]. We have previously profiled genome
wide gene expression in the whole ONH from 8.5 to
10.5 months of age to investigate disease progression
due to elevated IOP before and during neurodegenera-
tion [2, 3]. Notably these data pointed to major neuroin-
flammatory changes at a pre-degenerative stage of
disease, including changes in the complement system,
endothelin system, and cell-adhesion pathways. Our
group and others have experimentally validated mole-
cules in these pathways to demonstrate their importance
and role in glaucoma (from mouse to human [2, 12, 23–
29];). In addition, these pathways have been independ-
ently identified in other models of glaucomatous insult
and retinal ganglion cell death (ocular hypertension,
optic nerve crush, optic nerve transection / axotomy
[30–32]) supporting the utility of DBA/2 J retina and
optic nerve head tissue for modelling glaucoma. Despite
the importance of neuroinflammation in DBA/2 J glau-
coma, it remains unclear how microglia contribute to
disease progression.
To investigate the role of microglia in the ONH in re-
sponse to ocular hypertension, we performed RNA-
sequencing of mRNA from optic nerve head microglia at
a pre-degenerative stage of disease (9 months of age
prior to detectable optic nerve degeneration). Further-
more, we performed transcriptomic profiling of micro-
glia from radiation-treated mice, a potent and robust
anti-inflammatory and neuroprotective therapy for
DBA/2 J glaucoma [3, 33, 34]. Our results provide new
information about potential dysfunction of these cells.
We expect these data to be a novel resource for the
glaucoma and neurodegeneration community.
Methods
Mouse strain, breeding and husbandry
Mice were housed and fed in a 14 h light / 10 h dark
cycle with food and water available ad libitum; all mice
used in the study were female. All breeding and experi-
mental procedures were undertaken in accordance with
the Association for Research for Vision and Ophthal-
mology Statement for the Use of Animals in Ophthalmic
and Vision Research. The Institutional Biosafety Com-
mittee (IBC) and the Animal Care and Use Committee
(ACUC) at The Jackson Laboratory approved this study.
The DBA/2 J and DBA/2 J-GpnmbR150X (D2-Gpnmb+)
strains were utilized and have been described in detail
elsewhere [21]. Mice were used at 9 months of age when
the majority of eyes have had ongoing IOP elevation but
detectable neurodegeneration has yet to occur [2, 21,
35]. In DBA/2 J mice, mutations in two genes
(GpnmbR150X and Tyrp1b) drive an iris disease with fea-
tures of human iris atrophy and pigment dispersion. In
this disease, pigment disperses from the iris and induces
damage in the drainage structures of the eye. This in-
hibits aqueous humour outflow and leads to an increase
in intraocular pressure [36]. We used D2-Gpnmb+ mice
as a control, a non-glaucomatous substrain of DBA/2 J.
For radiation treated DBA/2 J mice, mice were placed on
a rotating platform and a sub-lethal dose of γ-radiation
(7.5 Gy; D2-RAD) was administered using a 137Cesium
source in a single dose at 10 weeks of age. Our previous
data has demonstrated that this level of treatment does
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not cause any adverse conditions and does not require
bone marrow reconstitution [3, 37]. The optic nerves of
all mice used in this study were confirmed to have no
detectable nerve damage or axon loss as assessed by
PPD staining (data not shown).
FAC sorting
FAC sorting of cells from the optic nerve head was per-
formed as previously described [37]. Prior to cell collec-
tion, all surfaces and volumes were cleaned with 70%
ethanol and RNaseZap (ThermoFisher Scientific) solu-
tion followed by dH20. Mice were euthanized by cervical
dislocation, eyes enucleated, and placed immediately into
ice-cold HBSS. For single ONH isolation, eyes were enu-
cleated from the globe with curved scissors and the eye
placed directly into ice cold HBSS (Gibco). The eye was
punctured at the limbus with a 28 G needle and the cor-
nea, iris, and lens removed to leave a posterior eye cup.
A single cut was made through the choroid to the tissue
surrounding the ONH, and the ONH (including the cen-
tral retina and some extraocular tissue and choroid) was
removed free from the globe. The ONH, representing
the transparent pre-myelin transition zone segment of
the optic nerve (~ 500 μm in length), was separated from
the central retina and myelinated optic nerve and any
additional pigmented tissue/extraocular tissue was re-
moved. Single ONHs were placed directly into 100 μl of
a custom HBSS, dispase (5 U/ml) (Stemcell Technolo-
gies), DNase I (2000 U/ml) (Worthington Biochemical),
and SUPERase (1 U/μl) (ThermoFisher Scientific) solu-
tion. Samples were incubated for 20 mins at 37 °C and
shaken at 350 RPM in an Eppendorf Thermomixer R
followed by gentle trituration using a 200 μl pipette.
Samples were blocked in 2% BSA, SUPERase (1 U/μl) in
HBSS, and stained with secondary conjugated antibodies
against CD11b, CD11c, CD34, CD45.2, GFAP (detailed
in Table 1), as well as DAPI. This cocktail allowed other
cell types to be accurately removed during FACS. FACS
was performed on a FACSAria (BD Biosciences). Singlet
gating of SSC-H vs SSC-W and FSC-H vs FSC-W gating
plots was used to identify single cells. FSC-H vs DAPI
was used to identify viable cells and CD11b+/CD45.2lo
(and negative for all other markers; Fig. 1a) microglia
were sorted into 100 μl buffer RLT + 1% β-ME, vortexed
and frozen at − 80 °C until further processing. We have
previously performed RNA-sequencing on mRNA of in-
filtrating monocytes (CD45hi/CD11b+/CD11c+) from the
optic nerve head of 9 month DBA/2 J mice [37]. This
marker panel was based on our previous findings that
identified the majority of infiltrating immune cells as
CD11c+ [3]. In these previous flow cytometry experi-
ments < 3% of all myeloid derived cells (CD45+/CD11b+)
in 9 month of age DBA/2 J optic nerve head tissue were
resident CD11c+ microglia (CD45lo/CD11b+) [3, 37], and
thus, CD11c+ microglia make up a negligible proportion
of optic nerve head immune cells at this time point. In
the current study, we aimed to enrich for resident
microglia, as opposed to microglia that may be derived
from infiltrating immune cells, and enriched for CD11c−
microglia for this purpose.
RNA-sequencing and analysis
Microglia samples were defrosted on ice and homoge-
nized by syringe in RLT Buffer (total volume 300 μl).
Total RNA was isolated using RNeasy micro kits as ac-
cording to manufacturer’s protocols (Qiagen) including
the optional DNase treatment step, and quality was
assessed using an Agilent 2100 Bioanalyzer. The concen-
tration was determined using a Ribogreen Assay from
Invitrogen. Amplified dscDNA libraries were created
using a Nugen Ovation RNA-seq System V2 and a pri-
mer titration was performed to remove primer dimers
from the sample to allow sample inputs as low as 50 pg
RNA. The SPIA dscDNA was sheared to 300 bp in
length using a Diogenode Disruptor. Quality control was
performed using an Agilent 2100 Bioanalyzer and a
DNA 1000 chip assay. Library size produced was ana-
lysed using qPCR using the Library Quantitation kit/Illu-
mina GA /ABI Prism (Kapa Biosystems). Libraries were
barcoded, pooled, and sequenced 6 samples per lane on
a HiSeq 2000 sequencer (Illumina) giving a depth of 30–
35 million reads per sample.
Following RNA-sequencing samples were subjected to
quality control analysis by a custom quality control py-
thon script. Reads with 70% of their bases having a base
quality score ≥ 30 were retained for further analysis.
Read alignment was performed using TopHat v 2.0.7
and expression estimation was performed using HTSeq
with supplied annotations and default parameters against
the DBA/2 J mouse genome (build-mm10). Bamtools v
Table 1 Flow cytometry antibody details
Antibody Fluorophore Source
Anti-mouse CD11b (clone M1/70) PE-Cy7 BD Biosciences, Cat # 552850
Anti-mouse CD11c (clone N418) PE Tonbo Biosciences, Cat # 50-0114-U025
Anti-mouse CD34 (clone RAM34) APC Thermo Fisher, Cat # 50-0341-82
Anti-mouse CD45.2 (clone 104) Brilliant Violet 421 Biolegend, Cat # 109831
Anti-human GFAP AF488 (pre-conjugated secondary) Abcam, Cat # ab4674
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1.0.2 were used to calculate the mapping statistics. Dif-
ferential gene expression analysis between groups was
performed using edgeR v 3.10.5 [38, 39] and the removal
of outlier samples and lowly expressed genes was
achieved by removing genes at a pre-defined cut-off
level. We only included genes that were expressed at > 1
counts per million (CPM) in ≥4 samples across all sam-
ples for D2-Gpnmb+ to DBA/2 J (D2) comparison and ≥
3 samples across all samples for D2 to D2-RAD com-
parison (chosen based on the size of the smallest group).
We used unsupervised hierarchical clustering (HC) to
generate clusters of samples with distinct gene expres-
sion profiles in which as many control samples were rep-
resented in a single cluster. HC was performed in R (1-
cor, Spearman’s rho) based on a matrix of all samples,
representing all genes post cut-off. Clusters were re-
quired to have ≥3 samples in order to compare using
statistical testing; clusters that did not meet these cri-
teria were removed from the analysis as outliers. (Al-
though D2 sample D2_S1 was more distant than others
within its cluster, analysing the data without this sample
made no changes to the outcomes, data not shown.) Ad-
justment for multiple testing was performed using false
discovery rate. DEseq2 and limma were used for differ-
ential expression analysis [40, 41]. Genes were consid-
ered to be significantly differentially expressed at a false
discovery rate (FDR; Benjamini and Hochberg adjusted p
values; q) of q < 0.05. Pathway analyses (see Results) were
performed in R, WebGestalt (www.webgestalt.org; pro-
vides continuously curated, publicly availably pathways
for exploring pathway enrichment) [42], and Ingenuity
pathway analysis (IPA, Qiagen; which further explores
directionality of pathway enrichment). Mitochondria
gene lists were taken from published lists [43, 44].
Graphing was performed in R. Complete raw untrimmed
count files can be found in Supplementary Data 1.
For comparisons to other published datasets, the
microglia dataset generated here was compared to DBA/
2 J whole optic nerve head at 8.5 months of age [2] (pub-
lically available from Datgan [45]) and DBA/2 J optic
nerve head monocytes at 9 months of age [37] (Supple-
mentary Data 2).
For the Supplementary Data 3 and 4, t refers to the t
statistic, and B refers to log-odds that the gene is differ-
entially expressed.
Results
Transcriptomic profiling of optic nerve head microglia
We performed RNA-sequencing on CD45lo/CD11b+/
CD11c− microglia samples from DBA/2 J (D2), control
D2-Gpnmb+, and radiation treated DBA/2 J (D2-RAD)
mice isolated from single optic nerve heads (ONHs) and
enriched through FAC sorting (see Methods, and Fig. 1a).
A total of 15 samples were amplified and sequenced
(n = 5 for all groups; cell inputs = 165 ± 37 for D2, 182 ±
145 for D2-Gpnmb+, and 162 ± 173 for D2-RAD). To
confirm the isolated cells were microglia, genes known
to be highly expressed in microglia, astrocytes, neurons,
oligodendrocytes, and infiltrating monocytes were ana-
lysed (Table 2). Genes associated with microglia were
highly expressed in these samples. Low to no expression
of other cell-type specific genes was observed, consistent
with the samples primarily containing microglia.
Differences between D2 samples were expected due to
the spontaneous nature of IOP insults, with some sam-
ples still resembling controls [35]. Hierarchical clustering
(HC) [2, 28] demonstrated that the majority of D2 sam-
ples were more similar to each other than to normoten-
sive D2-Gpnmb+ samples. HC generated two major
clusters of samples containing: (1) four D2 samples (D2_
S1–4), (2) five D2-Gpnmb+ samples (D2Gpnmb_S1–5)
and one D2 sample (D2_S5) (Fig. 1b). The D2 sample in
the second cluster (D2_S5) was removed for further ana-
lyses to create distinct disease (cluster 1; n = 4) and con-
trol (cluster 2; n = 5) groups. Between groups, 982 genes
were differentially expressed (DE, Fig. 1c and d, Supple-
mentary Data 3). Functional analysis of DE genes re-
vealed significant changes in pathways associated with
microglial function including surveillance, phagocytosis,
(See figure on previous page.)
Fig. 1 RNA-sequencing of optic nerve head microglia from D2 and D2-Gpnmb+ mice. Microglia were FAC sorted from freshly isolated optic nerve
heads and identified by being CD45lo/CD11b+ (a, see also Methods). Following RNA-sequencing of microglia from D2 and D2-Gpnmb+ optic
nerve heads, samples were grouped by unsupervised hierarchical clustering (b; blue = strong correlation, red = weak correlation), creating D2 and
D2-Gpnmb+ clusters (* denotes outlier excluded from subsequent analysis). c Genes were binned by log2 fold change (bin width 0.2) and
coloured to show DE genes (red; q < 0.05). A simple summary is shown in the inset of c. d Scatter plot of all genes by mean log2 counts per
million (CPM) for D2 (y) against D2-Gpnmb+ (x) showing DE genes (pink, q < 0.05; red, q < 0.001; non DE genes in grey) with top 20 DE genes
annotated. Pathway analysis of DE genes revealed dysregulation of pathways involved in the microglial sensome and metabolism (e and f.
Wikipathway analysis (e) showed significant dysregulation of 2 inflammatory pathways (q < 0.05). The number of DE genes within each pathway is
shown . Ingenuity pathway analysis (f) also showed dysregulation of a number of sensome and inflammatory pathways, and metabolism
pathways. Top 20 pathways sorted by z-score are shown, with the threshold for significant activation or inhibition marked. We queried
metabolism dysregulation (g) demonstrating a trend towards an increased ratio of mt-RNA:nu-RNA in D2 microglia (P = 0.23) and DE gene
expression (red, q < 0.05) in mitochondrial transcripts from nu-RNA and mt-RNA. DE of genes involved in OXPHOS and glycolysis/gluconeogenesis
(GNG). In f †PPRs = pattern recognition receptors
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metabolism, and inflammation (Fig. 1e and f), which are
further expanded on below.
Genes that regulate microglial surveillance and
phagocytosis are downregulated by chronic IOP elevation
A majority of the DE genes were downregulated in
microglia from D2 eyes (Fig. 1c). These downregulated
genes contributed to the enrichment of the TYROBP
causal network and microglial pathogen phagocytosis
pathways (Fig. 1e). The TYROBP causal network links
the activation of TREM2 receptors with gene expression
and thus contributes to the overall state of microglial ac-
tivation. The downregulation of numerous genes in the
network is consistent with a decrease in TYROBP signal-
ling [46]. Ingenuity Pathway Analysis (IPA) identified an-
other 19 pathways predicted to be significantly inhibited
or less active in D2 microglia compared to D2-Gpnmb+
microglia (Fig. 1f). These pathways span a wide range of
functions including phagocytosis, cell movement and
shape, receptor-mediated signalling, and inflammation.
Common downregulated DE genes within these path-
ways included C1 complex encoding genes (C1qa, C1qb,
C1qc), integrins (Itgam, Itgb2, Cd37), Ig superfamily
(Trem1, Trem2, Il10ra, Il13ra), phagocytic components
(Nckap1l) and toll-like receptor signalling (Tlr1, Tlr3,
Tlr7, and toll-like receptor pro-inflammatory enhancer
Themis2 [47]). These data predict that many functions
of microglia that help maintain tissue homeostasis are
affected, and potentially inhibited, by chronic ocular
hypertension.
Metabolism-related transcripts are upregulated in
microglia by chronic IOP elevation
Changes in genes with mitochondrial and metabolic
functions were identified in both gene and pathway level
analyses. Of the top 20 DE genes (sorted by q) in D2
microglia compared to D2-Gpnmb+, 10 were mitochon-
drial transcriptome derived (mt-RNA, Fig. 1d). Nuclear
encoded mitochondrial transcripts (nu-RNA) also dif-
fered from controls (22 up, 29 down, Fig. 1g). Ingenuity
pathway analysis predicted that these changes promote
oxidative phosphorylation (OXPHOS) activity (Fig. 1f).
17.5% of OXPHOS genes were DE and 19/20 DE genes
had higher expression in D2 mice (Fig. 1g). Changes in
the ratio of mt-RNA:nu-RNA can indicate changes in
intracellular signalling between the mitochondria and
nucleus. This ratio showed high variation between D2
samples (0.25 ± 0.17) but the mean ratio was not signifi-
cantly different from D2-Gpnmb+ samples (0.13 ± 0.02;
P = 0.23, Student’s t-test, Fig. 1g).
To further understand the metabolic state of micro-
glia, we considered additional changes in metabolic
genes. Hif1a, a master regulator of glycolysis and cell
stress responses [48], was upregulated consistent with
stress or inflammation, and with previous findings in the
inner retina during glaucoma [35, 49]. Glycolysis regula-
tor Pfkfb2 [50] was upregulated, as well as other glycoly-
sis genes (Gapdh, Pgam1, Pgk1, Pgm2l1) (Fig. 1g).
Slc16a1 (MCT1) was also up-regulated suggesting in-
creased lactate, pyruvate, or ketone bodies transport
[51]. The transporter is bi-directional, and as such could
reflect either an attempt to increase microglial energy
sources, or to increase metabolic support to retinal gan-
glion cell axons in the optic nerve head. Taken together,
these data suggest that optic nerve head microglia in
Table 2 Cell type specific gene expression
Cell type Gene Average expression (log2 CPM)
a
Myeloid Tmem119 9.53
Myeloid P2ry12 9.93
Myeloid Siglech 8.53
Myeloid Gpr34 7.79
Myeloid Olfml3 9.06
Myeloid Cx3cr1 10.88
Myeloid Aif1 (Iba1) 7.23
Myeloid (activated) Itgax 4.66
Myeloid (activated) Ccr2 3.73
Myeloid (activated) Ly6c1 0.94
Myeloid (activated) Mrc1 (CD206) 4.89
Myeloid (activated) Cd68 8.60
Astrocyte Gfap 0.80
Astrocyte Gjb6 N.D
Astrocyte Ntsr2 N.D
Astrocyte Aldh1l1 −0.50
Astrocyte Aldoc N.D
Astrocyte Aqp4 0.38
Oligodendrocyte Mobp N.D
Oligodendrocyte Mog N.D
Oligodendrocyte Cldn11 N.D
Oligodendrocyte Plp N.D
Neuronal Tubb3 N.D
Neuronal Vglut1 N.D
Neuronal Rpbox3 (NeuN) N.D
Neuronal Syt1 1.75
Neuronal Stmn2 N.D
Neuronal Snap25 3.44
Neuronal Eno2 2.52
Neuronal Syn1 N.D
Housekeeping Actb 12.09
Housekeeping Gapdh 9.35
N.D not detected (below cut-off), a average across all D2 and
D2-Gpnmb+ samples
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D2s develop an increased capacity to metabolise energy
from various sources.
Metabolic switching between oxidative phosphorylation
and glycolysis occurs in disease when microglia transition
between pro-inflammatory and anti-inflammatory states.
This cellular transition is associated with gene expression
changes induced by both ROS and cytokine signalling
pathways. In optic nerve head microglia, no enrichment
was observed in pro or anti-inflammatory pathways based
on the number of DE genes (Fig. 1e). Based on the direc-
tion of expression changes, three pro-inflammatory path-
ways were predicted to be inhibited; neuroinflammation
signalling, Th1 signalling, and inflammasome signalling
(Fig. 1f). We also assessed changes in a list of 20 genes as-
sociated with canonical M1 and M2 inflammation pheno-
types [52]. Only two genes were differentially expressed,
Ccl5 (decreased) and Tgfb2 (increased). TGF-β is an im-
portant anti-inflammatory signal for microglia that regu-
lates their morphology, proliferation, and survival [53].
TGF-β signalling has been implicated in both homeostatic
and anti-inflammatory signalling in microglia. Overall
microglia gene expression in response to chronic IOP ele-
vation was not pro-inflammatory, although they are pre-
dicted to be primed metabolically to facilitate rapid
changes in phenotype.
Microglia and infiltrating monocytes have distinct
phenotypes in pre-degenerative tissue
We compared gene expression changes in the isolated
D2 microglia to previously defined gene expression
changes from whole ONH tissue [2, 3] and from infil-
trating monocytes [37] both from D2 mice at similar
ages (Fig. 2, Supplementary Data 2). Howell et al. previ-
ously identified 5 molecularly distinct stages of disease
in the D2 whole optic nerve head using hierarchical
clustering of RNA microarray data, where stages 1–3
show no morphologically detectable neurodegeneration.
A further 3 early stages (between stage 1 and 2) were
subsequently identified [2, 3]. Based on corresponding
upregulation or downregulation of genes, there was par-
tial overlap between expression changes in isolated D2
microglia and each staged group of ONH samples
(Fig. 2a). The most overlap with the D2 ONH was at an
ocular hypertensive and pre-degenerative stage, repre-
senting 0.7% of DE genes in the ONH and 8% in micro-
glia. A similar comparison between infiltrating
monocytes and the ONH showed greater overlap, with
4-fold more genes in common. Very few DE genes
showed the same directional DE changes across all 3
groups (Fig. 2b). A comparison irrespective of directional
regulation showed a larger number of common DE
genes between either microglia or monocytes with whole
optic nerve head tissue (Fig. 2c), possibly as cell-specific
effects may be masked in whole tissue analysis. Taken
together, these data suggest that these two myeloid-cell
derived populations have largely distinct responses rela-
tive to whole tissue changes in the ONH after chronic
ocular hypertension.
To further elucidate the neuroinflammatory and meta-
bolic phenotypes, we compared neuroinflammatory and
mitochondria gene expression in microglia and mono-
cytes (Fig. 2d and e). Of 144 neuroinflammatory genes
annotated by Ingenuity, few were DE in either microglia
(n = 18) or monocytes (n = 16) at this pre-degenerative
stage of disease (Fig. 2d). The shared neuroinflammatory
DE genes (n = 5) showed the same direction of change in
both cell types (Fig. 2e). These five genes (Cx3cr1, Tgfb2,
Tgfbr1, Trem2, and P2rx7) offer excellent candidates for
genetic manipulation to test function of innate immune
pathways in the optic nerve head.
Metabolic changes are a prominent feature in cells and
tissue affected by elevated IOP based on RNA-
sequencing datasets [35, 37, 54]. Changes to transcripts
encoding mitochondrial proteins feature in both the
microglia and monocyte RNA-sequencing datasets
(Fig. 2d and e). Dysregulation of nu-RNA was greater in
monocytes (n = 121 genes) than microglia (n = 48 genes).
Of the 10 shared DE nu-genes, 7 showed the same direc-
tional change (Fig. 2e) but with a greater magnitude of
dysregulation in monocytes. For mt-RNA transcripts 12/
15 genes were DE in both monocytes and microglia, but
with markedly different expression profiles (0/12 being
co-up- or co-down- regulated; Fig. 2e). Thus, our data
suggest a pro-metabolic status in microglia that is not
matched in infiltrating monocytes. Together our data
implicate mitochondrial / metabolic changes in optic
nerve head immune cells as an early disease feature.
Pre-treatment by irradiation reduces the effects of ocular
hypertension on microglia
Low dose irradiation of mice at a young age prevents
glaucomatous neurodegeneration in D2 mice without
lowering IOP [3]. Altered microglia have been suggested
to contribute to the protective effects of radiation [34].
We compared and analysed D2 against RAD-D2 sam-
ples. HC generated 2 clusters representing 1) three D2
samples (D2_S1, 2, and 4), and 2) five RAD-D2 samples
(D2-RAD_S1–5) and 1 D2 sample (D2_S3) (Fig. 3a).
This single D2 sample from cluster 2 was removed by
the dendogram cut (Fig. 3a). RAD-D2 microglia exhib-
ited 2246 DE genes compared to D2 microglia (783 up-
regulated, 1463 downregulated) (Fig. 3b and c,
Supplementary Data 4). Pathway analyses (Fig. 3d-f)
showed that radiation treatment affects phagocytosis,
metabolism, mitochondria, and inflammation related
genes, all pathways altered in microglia (see above).
There were 579 genes altered by radiation that over-
lapped with changes in glaucoma (D2 vs. D2-
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Gpnmb+comparison). For 578 of these genes, radiation
treatment corrected the disease-related change (Fig. 3f).
Dcbld2 was the single gene DE downregulated in both
datasets. Dcbld2 encodes the endothelial and smooth
muscle cell-derived neuropilin-like protein (ESDN)
which is upregulated in endothelial cells following vascu-
lar injury [55]. Its deletion or downregulation impairs
retinal angiogenesis [56] and promotes insulin signalling
[57]. Its expression is not limited to endothelial cells;
with relatively robust expression in microglia, astrocytes,
and neurons (brain RNA-sequencing [58]).
Discussion
Neuroinflammation at the site of the optic nerve head
(ONH) may be a critical pathogenic event in glaucoma.
Our group and others have identified the ONH as a
likely candidate for the initial site of damage in glau-
coma across species [22, 59–61]. In this manuscript we
have identified further transcriptomic changes at the
level of ONH microglia. The current study focuses on
CD11c− microglia, the most prominent microglia sub-
type in our previous datasets (representing > 97% of
microglia identified in the ONH, [3, 37]). We have previ-
ously used CD11c as a marker to distinguish myeloid-
derived cell subtypes within the ONH; with the majority
of infiltrating monocyte-like cells in the ONH being
CD45hi and CD11c+. Emerging evidence is demonstrat-
ing a role for CD11c+ microglia in neurodegenerative
disease progression, especially during demyelinating
events [62], and with T-cell interactions in the brain
[63]. Given that the ONH is unmyelinated, and that T-
cell changes have not been found in the glaucomatous
ONH, it is unsurprising to observe so few CD11c+
microglia. Here, we focused on Cd11c− microglia, a sub-
type more associated with tissue surveillance and inflam-
mation. These microglia were affected by chronic ele-
vated intraocular pressure (IOP) based on changes at a
transcriptional level, consistent with previous studies
showing microglial activation in glaucoma.
To explore molecular changes that lead to optic nerve
degeneration we have previously performed microarray
gene expression profiling of the whole ONH [2, 3]. This
data set shows changes to inflammatory pathways, but
the attributive cells were unknown. To further under-
stand the molecular events that happen in the ONH at a
cell-type level we have performed transcriptomic profil-
ing of monocyte-like cells in the same model of glau-
coma [37]. These cells were highly pro-inflammatory
and express various complement genes and integrins.
Targeting the α subunit of complement receptor 3 (gen-
etic ablation of Itgam encoding CD11b) prevents
monocyte-like cell extravasation into the ONH and sig-
nificantly reduced the risk of developing severe glau-
comatous neurodegeneration. CD11b is well expressed
on microglia [64] and we used cell-surface expression of
CD11b to enrich for microglia. In the data presented
here we predict that DBA/2 J microglia are initially anti-
inflammatory. Itgam is downregulated in DBA/2 J micro-
glia (in this data set) following periods of ocular hyper-
tension. Nevertheless, the protection that results from
removing CD11b (Itgam knockout [37];) could, in part,
be due to its effects on microglia, but elucidating exactly
which cell-type is at play will take definitive testing using
cell-type-specific cre-lines. This dichotomy of microglia
and monocytes in the ONH offers an exciting avenue for
further research, particularly during the stage of mono-
cyte extravasation into the ONH. For example, microglia
processes have been shown to reseal injured capillaries
following recruitment via P2ry12 mediated chemotaxis
[65]. P2ry12 is downregulated in D2 microglia in the
present study, which could suggest defects in initial-
protective microglial responses that exacerbate mono-
cyte initiated injury.
To date, one of the most protective therapies in DBA/
2 J glaucoma has been radiation therapy [3, 6, 33, 34]. A
sub-lethal dose of radiation (γ- or X- ray) early in life
changes the neuroinflammatory response to ocular
hypertension later in life. One reason that radiation
treatment is protective is that it increases the expression
(See figure on previous page.)
Fig. 2 Monocytes, not microglia, are likely drivers of inflammatory signatures in glaucoma gene expression datasets. Comparison between DE genes
in microglia (Tribble; current dataset), monocytes (Williams [37];), and whole optic nerve head in the D2 (Howell [2, 3];). Howell et al. [2] previously
identified 5 molecularly distinct stages of disease in the D2 whole optic nerve head, where stages 1–2 show no morphologically detectable
neurodegeneration. Further study subdivided stage 1 into 3 stages (1a, 1b, and 1c as shown between stages 1 and 2 here) [3]. a Euler diagrams
show total number of DE genes within each dataset (number within each circle), the number of shared DE genes (with matching upregulation or
downregulation, shown outside the corresponding intersection, and centrally (in red text) for matching genes for all 3 datasets (also displayed in
b). c When direction of change is not considered, there are a greater number of shared DE genes for both microglia and monocytes, but a
greater percentage of these are of matching upregulation or downregulation in monocytes. This may reflect strength of contribution of
monocytes to whole optic nerve head changes over microglia. Further comparisons of neuroinflammatory genes (based on IPA gene sets) or
mitochondria-related transcripts (from MitoCarta [43, 44]) demonstrate a number of genes that are uniquely DE in either microglia or monocytes
(d; red = DE in microglia, blue = DE in monocytes; log2 CPM from D2 microglia and D2 infiltrating monocytes). Of the few shared DE genes (d;
purple) the majority of neuroinflammatory and nu-genes show the same directional changes but the opposite was true for mt derived genes (e;
upregulation = red, downregulation = blue)
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of GlyCAM1 in the retina and ONH, thereby reducing the
entry of pro-inflammatory monocytes [6]. Another type of
neuroinflammatory cell-type affected by radiation therapy
is microglia [34]. Microglia respond acutely to radiation
therapy; however, the long-term effects on microglia need
to be more fully defined. As presented here, the majority of
genes (59%) dysregulated by elevated IOP in untreated
DBA/2 J microglia had a different level of expression in D2-
RAD microglia. In addition, microglia in treated mice had a
different predicted activation state of TREM1 signalling and
more broadly alterations of neuroinflammation signalling
and metabolic pathways related to energy production
(Fig. 3d). It is not clear yet whether this is a direct effect of
the radiation treatment within microglia or a secondary ef-
fect of microglial interactions with other cells. TREM1 sig-
nalling may be a critical factor in controlling microglial
activation in glaucoma and needs to be tested further. De-
termining the function of TREM1 signalling in glaucoma is
likely to uncover more specific mechanisms of damage by
elevated IOP and protection by radiation therapy.
Phagocytosis is suggested to be a critical process in the
ONH for healthy tissue maintenance [66], but its role in
ONH microglia has not been explored. Microglial
phagocytosis is generally regulated by the TREM2-
TYROBP signalling pathway [67], and the TYROBP sig-
nalling network in microglia is among the earliest af-
fected by chronic elevated IOP. Mutations in TYROBP
cause Nasu-Hakola disease [68], in which the neurode-
generative pathology is defined as a primary microglial
disorder [69]. This underlies the important function of
this pathway and microglia toward directly preventing
disease. Disruption of the TYROBP signalling network
has also been demonstrated in Alzheimer’s disease [46].
Furthermore, the increased risk of Alzheimer’s disease
caused by TREM2 mutations [70] has led to research
showing many effects of TREM2 on phagocytosis, tran-
scription, metabolism, and inflammation [71–73]. These
data suggest that this signalling pathway may be a mas-
ter regulator of other changes observed here. Manipulat-
ing TYROBP and TREM2 is a promising strategy to
define functions of microglia in glaucoma and a possible
avenue for treatment.
Retinal ganglion cell axons remain unmyelinated at
the ONH and therefore are particularly vulnerable to
glaucoma related stresses (age and elevated intraocular
pressure) in addition to metabolic strain. Recently we
have demonstrated that a critical metabolic vulnerability
exists in retinal ganglion cells in DBA/2 J glaucoma with
marked mitochondrial and metabolic changes [35]. Pre-
venting these metabolic events (either systemically or
specific to retinal ganglion cells) robustly protects from
glaucomatous neurodegeneration [25, 54] although neu-
roinflammatory features still remain [25]. The neuro-
glia-vascular complexes of the ONH form a contained
metabolic unit in which glia provide trophic and meta-
bolic support to retinal ganglion cell axons [74]. In our
data, microglia are predicted to become more metabolic-
ally active, a metabolic shift that is typically anti-
inflammatory and pro-supportive to neurons [75]. In this
sense, microglia could be early mediators of neuropro-
tection in glaucoma. More work is needed to explore
microglial function at different stages of disease, along
with a consideration of microglial subtypes. One sub-
type, CD11c+ microglia, represent a small proportion of
ONH microglia in our early-stage data, but may become
important at later stages or in other regions of affected
tissue. It is also possible that microglia later become
pro-inflammatory. Thus further experiments are needed
to resolve how elevated IOP triggers changes in micro-
glia and if polarization of microglia continues to change
during disease progression.
Metabolic treatments that protect retinal ganglion cells
do not prevent all neuroinflammatory events in the ret-
ina and ONH [25, 35]. The long-term effects of this neu-
roinflammation on survival or function of the optic
nerve are not known. Thus, inflammation remains an
important target to consider for new therapies. At this
pre-degenerative stage of glaucoma, we observed few
changes in inflammatory molecules in microglia, and at-
tribute many of the neuroinflammatory changes to infil-
trating monocyte-like cells. Recent evidence using single
cell RNA-sequencing has demonstrated that microglia
display a heterogeneous repertoire of inflammatory re-
sponses in diseased tissue. Our study may lack the
(See figure on previous page.)
Fig. 3 RNA-sequencing of optic nerve head microglia from D2 and radiation therapy treated D2 mice. Following RNA-sequencing of microglia form
D2 and radiation therapy treated (RAD-D2) optic nerve heads, samples were grouped by unsupervised hierarchical clustering (a; blue = strong
correlation, red = weak correlation), creating D2 and RAD-D2 clusters (* denotes outlier excluded from subsequent analysis). b Genes were binned
by log2 fold change (bin width 0.2) and coloured to show DE genes (red; q < 0.05). A simple summary is shown in the inset of b. (c) Scatter plot
of all genes by mean log2 counts per million (CPM) for D2 (x) against RAD-D2 (y), showing DE genes (pink, q < 0.05; red, q < 0.001; non DE genes
in grey) with top 20 DE genes annotated. Ingenuity pathway analysis (d) showed dysregulation of a number of sensome and inflammatory
pathways, and metabolism pathways, representing a correction of the D2 phenotype in RAD treated animals. Top 20 pathways sorted by z-score
are shown, with the threshold for significant activation or inhibition marked. Relevant to metabolism and signaling (e) mt-RNA:nu-RNA ratios are
shown. DE gene expression (red, q < 0.05) in mitochondrial transcripts in nu-RNA and mt-RNA are shown. Genes involved in OXPHOS and
glycolysis/gluconeogenesis (GNG) are compared. f Overlap of DE genes from D2 vs. D2-Gpnmb+ and D2 vs. RAD-D2 datasets. In e †PPRs = pattern
recognition receptors
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cellular resolution to detect microglial heterogeneity as-
sociated with inflammation, if present. However, reactive
microglia in the ONH have been identified immunohis-
tochemically in glaucoma [5, 7] and more precisely char-
acterizing the timing and cellular heterogeneity of such
changes will provide deeper insights into glaucoma
pathophysiology.
Metabolic regulation is an important aspect of myeloid-
derived cell polarity and function. Resident microglia can
exhibit similar M1/M2 phenotypes to peripheral macro-
phages, the former representing an activated, pro-
inflammatory phenotype and the latter a resting, anti-
inflammatory phenotype [75]. An M1 state is consistent
with aerobic glycolysis, where metabolic resources can be
directed towards cell proliferation and activation, and
where the ROS generated for phagocytic clearance will not
interfere with and uncouple electron transport [76]. An M2
polarisation state is consistent with increased glucose me-
tabolism and mitochondrial biogenesis [77]. Microglia in
our dataset did not conform to either phenotype; we ob-
served increased expression in glycolysis genes (including
Hif1a), but also an upregulation of OXPHOS genes. In fact,
the microglia exhibited increased metabolic upregulation
from multiple energy sources. RNA sequencing of micro-
glia in neurodegenerative disease has shown that microglial
exhibit more nuanced states than these simple M1 and M2
polar opposites [14, 72, 78–80]. There is also evidence to
suggest that dysregulation of metabolism and accumulation
of mt-DNA mutations within microglia may itself be a trig-
ger for microglial activation in neurodegenerative disease
[81]. Dysregulated metabolism in microglia may also impair
their ability to mitigate neuroinflammation. Trem2−/−
5XFAD mice (an Alzheimer’s disease model) show im-
paired glycolysis, reduced ATP production, and increased
autophagy in microglia. This disruption to metabolism may
contribute to the reduced microglial phagocytosis observed
in Trem2−/− 5XFAD mice. Microglia in aged mice also dis-
play upregulated oxidative phosphorylation and utilisation
of ketone energy sources, which may represent a stress re-
sponse or loss of transcriptional regulation [82]. The dys-
regulation of metabolism seen in D2 microglia may be
indicative of metabolic stress which may perturb microglial
responses to neuroinflammation. Therapeutic strategies
that target microglia metabolism may be valid targets for
glaucoma treatment.
Conclusions
This study identifies alterations in mitochondrial gene
expression as well as changes to phagocytosis, inflamma-
tory, and sensome pathways in microglia prior to optic
nerve degeneration in DBA/2 J glaucoma. Out of this
complex set of changes, the TREM/TYROBP signalling
network emerged as a potential master regulator of
microglial responses to elevated IOP. This type of
response is observed in other neurodegenerative diseases
where homeostatic functions of microglia are suppressed
by inhibition of TYROBP signalling. This occurred in
the absence of a clear pro-inflammatory response by
microglia, suggesting that early pro-inflammatory signals
may largely derive from infiltrating monocyte-like cells
in this model of glaucoma. These data shed new light on
the early myeloid changes in the ONH following periods
of ocular hypertension and offer novel targets for treat-
ment and further mechanistic exploration.
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